ReviewSeminars in liver disease2021
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity.
Review in Seminars in liver disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- The association between steatotic liver disease and chronic kidney disease: a meta-analysis and Mendelian randomization study highlighting metabolic comorbidities.Nutrition & diabetes · 2026Pooled it
- Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD.Journal of gastroenterology · 2022Pooled it
- Effects of Synbiotics, Probiotics, and Prebiotics on Liver Enzymes of Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis.Frontiers in nutrition · 2022Pooled it
- Time-Varying Impact of Steatosis and Alcohol on Mortality: A Marginal Structural Model of the Canadian Longitudinal Study on Aging.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management.Nature reviews. Gastroenterology & hepatology · 2026Review
- The global cardiovascular-liver-metabolic syndemic: epidemiology, trends and challenges.Nature reviews. Cardiology · 2026Review
- Clinically distinct metabotypes of pediatric MASLD identified through unsupervised clustering of NASH CRN data.Nature communications · 2026Article
- MASLD Under the Umbrella of the Microbiota: A Narrative Review on Ecological Risk and Functional Transmissibility.Journal of clinical medicine · 2026Review
- An interpretable machine learning model for prediction of significant liver fibrosis in comorbid chronic hepatitis B and nonalcoholic fatty liver disease: a retrospective development and validation study.BMC gastroenterology · 2026Article
- Panomics in metabolic dysfunction-associated steatotic liver disease: unravelling the drivers of disease heterogeneity.Clinical and molecular hepatology · 2026Review
- Article
- Effects and safety of Huatan Qushi Huoxue granules on obesity-associated non-alcoholic fatty liver disease: a multicenter, randomized, double-blind, placebo-controlled trial.Frontiers in pharmacology · 2026Article
- MetALD: New Perspectives on an Old Overlooked Disease.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Characterization of Extracellular Vesicles Derived From Human Precision-Cut Liver Slices in Metabolic Dysfunction-Associated Steatotic Liver Disease.Journal of extracellular biology · 2025Article
- Design and rationale for a global novel non-invasive screening observational study using genetics and non-invasive methodologies to identify at-risk MASLD participants: The ALIGN study.Contemporary clinical trials communications · 2025Article
- Risk of Serious Bacterial and Non-Bacterial Infections in People With MASLD.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives.Molecular oncology · 2025Review
- Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease.Clinical and molecular hepatology · 2025Review
- Extracellular vesicles and microRNAs in metabolic dysfunction-associated steatotic liver disease: from steatosis to hepatocellular carcinoma.EXCLI journal · 2025Article
- Gut microbiota heterogeneity in non-alcoholic fatty liver disease: a narrative review of drivers, mechanisms, and clinical relevance.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
Abstract
The acronym nonalcoholic fatty-liver disease (NAFLD) groups a heterogeneous patient population. Although in many patients the primary driver is metabolic dysfunction, a complex and dynamic interaction of different factors (i.e., sex, presence of one or more genetic variants, coexistence of different comorbidities, diverse microbiota composition, and various degrees of alcohol consumption among others) takes place to determine disease subphenotypes with distinct natural history and prognosis and, eventually, different response to therapy. This review aims to address this topic through the analysis of existing data on the differential contribution of known factors to the pathogenesis and clinical expression of NAFLD, thus determining the different clinical subphenotypes observed in practice. To improve our understanding of NAFLD heterogeneity and the dominant drivers of disease in patient subgroups would predictably impact on the development of more precision-targeted therapies for NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.